Home » Archives by category » Consensus
Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) | EAS Consensus Panel

Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) | EAS Consensus Panel

2016 European Guidelines on cardiovascular disease prevention in clinical practice.

2016 European Guidelines on cardiovascular disease prevention in clinical practice.

2016 European Guidelines on cardiovascular disease prevention in clinical practice. The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation […]

ESC/EAS Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk

ESC/EAS Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk

Introduction Atherosclerotic cardiovascular disease (ASCVD) underlies the thrombotic events intimately associated with myocardial infarction, a significant proportion of ischaemic strokes, as well as critical limb ischaemia. Such events confer substantial mortality, physical and/or mental disability, and cost for the individual and society. Indeed, no finite value can be attributed to the cost to the individual, […]

Slide set | 2016 European Guidelines on CVD Prevention in clinical practice.

Slide set | 2016 European Guidelines on CVD Prevention in clinical practice.

2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk.

2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk.

PREFACE The American College of Cardiology (ACC) develops a number of clinical policy documents to provide members with guidance on clinical topics. Although clinical practice guidelines remain the primary mechanism for offering evidence-based recommendations, such guidelines may contain gaps in their guidance regarding clinical decision making, particularly when equipoise is present in a topic. Expert Consensus Documents are intended […]

Consensus Statement of the European Atherosclerosis Society on Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease.

Consensus Statement of the European Atherosclerosis Society on Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease.

Even at low-density lipoprotein cholesterol (LDL-C) goal, patients with cardiometabolic abnormalities remain at high risk of cardiovascular events. This paper aims (i) to critically appraise evidence for elevated levels of triglyceride-rich lipoproteins (TRLs) and low levels of high-density lipoprotein cholesterol (HDL-C) as cardiovascular risk factors, and (ii) to advise on therapeutic strategies for management. Current evidence supports […]

Joint consensus  statement from the European Atherosclerosis  Society and European Federation of Clinical  Chemistry and Laboratory Medicine

Joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine

Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points. Read here the full article